NRX PHARMACEUTICALS INC (NRXP)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$2.27-8.84%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · NRXP
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 56.9% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
NRXP — litigation filed
Dated 2026-11-02
Regulation FD Disclosure. On October 30, 2026, NRx Pharmaceuticals, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (the “FDA”) has approved the Company’s Abbreviated New Drug Application (“ANDA”) for Preservative-Free Ketamine, ahead of the November 10, 2026 goal date established under the Generic Drug User Fee Amendments (“GDUFA”). The Company also hosted a conference call and live webcast at 8:30 a.m. Eastern Time on October 30, 2026 to discuss the approval. A cop…
Why it matters: The report can show if early revenue grows and cash still covers at least one year of operations.
Watch forRevenue rises above the $1.1 million reported for 2026-Q2, and cash guidance still covers at least one year.
Also watch forRevenue is $1.1 million or less, or management says cash no longer covers one year of operations.
Why it matters: The company is making five million doses for launch. Sales would show whether its launch plan is turning into business.
Supportive ifThe company reports first commercial sales in 2026 and confirms five million launch doses are ready.
Worry ifThe company reports no 2026 sales or says launch stock is not ready by year-end.
Why it matters: The contract can fund an NRX-101 trial with robotic TMS. It may also test the drug in a wider group of patients.
Supportive ifThe company reports receipt of DARPA funds and starts the Phase 2/3 SPARC-TMS trial.
Worry ifDARPA funding is not received, or the company reports the trial has not started.
Why it matters: The FDA's decision is the next gate for the planned 2026 launch. The company has sent the requested vial statement.
Supportive ifThe FDA approves the ANDA or clears the last vial-label issue, with no new major deficiency.
Worry ifThe FDA sends a new major deficiency letter or does not clear the vial issue by year-end 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$238 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $848 loss on $10,000 · 8.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,303 loss on $10,000 · 53.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.